Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Longeveron appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer effective August 17, 2026. The filing discloses his extensive 25+ years of biopharma leadership experience, prior CFO roles at public biotech companies (Opus Genetics, Insilico Medicine, Journey Medical), and his compensation package including $400,000 base salary, 45% performance bonus target, and 300,000 RSUs vesting over three years. This is a material executive appointment to a principal officer role at a clinical-stage biotech company.
View raw filing on EDGAR →
6-K
Other material
confidence 65%
filed 2026-08-19
The 6-K discloses an adjustment to the exercise price of three series of warrants (Series A Warrants issued January 29, 2024; June 2026 PIPE Warrants; and June 2026 Note Warrant) effective August 18, 2026, reducing the exercise price to $2.215928 per share. This is a material adjustment to the terms of outstanding equity instruments that affects the dilution profile and economic value of the warrants. While the adjustment appears to be a mechanical application of anti-dilution provisions rather than a discrete corporate event, it materially affects warrant holders' rights and the company's potential dilution, warranting disclosure to investors. The event does not fit neatly into a specific category (not an issuance, not compensation, not a restatement) but is clearly material and financial in nature.
View raw filing on EDGAR →
6-K
Earnings release
confidence 97%
filed 2026-08-19
EX-99.4
TOYO Co., Ltd disclosed unaudited financial results for the second quarter and first half of 2026, reporting H1 revenue of $261.0 million (up 87.6% YoY), net income of $45.8 million (up 1,731.6% YoY), and diluted EPS of $1.20, with gross margin of 32.5%. The disclosure includes detailed consolidated financial statements and was furnished via both a press release and investor presentation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-19
Item 5.07
This Item 5.07 disclosure reports the results of Forum Markets' 2026 Annual Meeting of Stockholders held on August 19, 2026, including voting outcomes on three proposals: election of three Class II directors (McAndrew Rudisill, Ryan Smith, and Jason New), advisory approval of named executive officer compensation, and ratification of M&K CPAS, PLLC as independent auditors. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-19
EX-99.1
Linkage Global Inc is soliciting shareholder approval for a 23:1 share consolidation and adoption of amended memorandum and articles of association at an extraordinary general meeting scheduled for September 8, 2026. The consolidation is motivated by Nasdaq's minimum bid price rule to avoid delisting risk.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-19
EX-99.1
This press release announces a significant operational milestone: SuperX's Japan Global Supply Center has delivered Pro6000 servers worth US$31 million to Digital Dynamic Inc. and secured new orders totaling approximately US$20 million, with cumulative expected shipments of US$38 million by end of August 2026. The disclosure highlights the expansion of SuperX's regional delivery capacity, establishment of a localized supply chain hub, and deepening strategic partnership with a major customer. While this is a material business development demonstrating operational scale and market validation in a key geographic market, it does not fit the specific event categories (not an earnings release, M&A activity, debt issuance, or other discrete event types), making it an operational business milestone best classified as operational_other.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-19
Item 8.01
Aditxt entered into and closed a Stock Purchase Agreement on August 12, 2026, whereby MDNA Holdings Inc. acquired substantially all outstanding shares of Pearsanta, Inc., Aditxt's majority-owned subsidiary. This constitutes a material disposition of a subsidiary with ongoing royalty and milestone payment obligations to the Company, directly fitting the definition of M&A activity (Item 1.02 / 2.01 territory, disclosed under Item 8.01). The transaction is material as it involves the sale of a significant operating subsidiary and establishes future contingent revenue streams.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-19
The 6-K discloses governance changes contingent on the closing of a previously announced merger with MBody AI. The Board has determined independence status for four directors and announced the expected post-closing composition of three Board committees (Audit, Compensation, Nominating). While the merger itself was previously disclosed and approved by shareholders in November 2025, this filing announces specific governance restructuring tied to the anticipated merger closing, which is material to investors assessing post-transaction leadership and oversight structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-19
Item 7.01
HeartSciences issued 411,522 shares of common stock to Fortitude Mining Holdings in a private placement at $2.43 per share for approximately $1 million on August 12, 2026. This is a classic dilutive equity issuance in connection with a proposed business combination. The filing explicitly describes it as a "private placement" and notes that Fortitude now holds approximately 9.4% of HeartSciences' outstanding shares. While the transaction is also related to an ongoing M&A activity (the proposed merger with Fortitude), the primary disclosed event is the equity issuance itself, which is material to existing shareholders due to dilution.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-19
The filing discloses entry into an underwriting agreement on August 18, 2026, for the issuance and sale of $85 million in aggregate principal amount of 8.00% Notes due 2031, with an additional $12.75 million greenshoe option. Item 1.01 explicitly states "Entry into a Material Definitive Agreement" and Item 2.03 incorporates the debt creation. The filing also discloses a concurrent redemption of $105.5 million of existing 6.00% Notes due 2027 using proceeds from the new offering. This is a material debt issuance creating a direct financial obligation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-19
Item 1.01
The Company entered into a Securities Purchase Agreement on August 19, 2026, to sell $275,000 in principal amount of Debentures and conditional warrants in a private placement to accredited investors under Section 4(a)(2) and Regulation D exemptions. The Debentures automatically convert to Common Stock upon a future Public Offering, and the Warrants are exercisable for additional Common Stock, creating significant dilution contingent on future capital raising. This is a classic dilutive private placement raising cash through unregistered securities with conversion and warrant features that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-19
Item 3.01
OSR Health received a Staff Delisting Determination from Nasdaq on August 19, 2026, notifying the company that its common stock and warrants will be delisted from the Nasdaq Capital Market due to failure to maintain the minimum $1.00 closing bid price required by Nasdaq Listing Rule 5550(a)(2). Trading suspension is scheduled for August 26, 2026, with formal delisting to follow unless the company successfully appeals to the Nasdaq Hearings Panel.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-19
Item 1.01
Silo Pharma entered into an asset purchase agreement with Parkview Consulting LLC to acquire software, technology, domain names, and related intellectual property in exchange for 165,000 shares of common stock. The transaction involves a related party and constitutes a material acquisition of assets.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-19
Item 7.01
This Item 7.01 disclosure concerns a proposed business combination between Plum Acquisition Corp. IV (a SPAC) and Controlled Thermal Resources Holdings Inc., with a Business Combination Agreement entered into on March 12, 2026. The filing furnishes an updated investor presentation related to the transaction and references the forthcoming Form S-4 registration statement and proxy statement/prospectus. This is a material M&A activity—specifically a SPAC merger—that would result in a change of control and is central to the disclosure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-19
Item 7.01
The filing discloses the declaration of monthly cash dividends on two series of preferred stock: $0.2708333 per share for the 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock and $0.20833 per share for the 10.00% Series E Cumulative Redeemable Perpetual Preferred Stock, with record and payment dates specified. This is a routine but material dividend distribution to preferred shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-19
Item 7.01
MVB Financial Corp. announced a quarterly cash dividend of $0.17 per share payable September 15, 2026, to shareholders of record as of September 1, 2026. This is a routine declaration of a regular quarterly dividend, consistent with the prior quarter, disclosed via press release in Item 7.01 (Regulation FD Disclosure). Dividend declarations are material to investors as they represent a return of capital and signal management confidence in cash generation.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-19
EX-99.1
Aurora Cannabis has disclosed an unsolicited take-over bid by Curaleaf Holdings, Inc. for all issued and outstanding common shares at US$4.00 per share (0.3463 Curaleaf subordinate voting shares plus US$0.75 cash), with a cap at US$5.00 per share. This is a material acquisition/change-of-control event requiring disclosure under Item 1.01 or 2.01 of the 8-K taxonomy. The company's Board has formed a special committee to evaluate the offer and will provide a formal recommendation within 15 days, and the offer remains open for a minimum of 105 days. This is clearly material to shareholders and would significantly affect the registrant's future.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-19
EX-99.1
This news release announces the first batch of drill results from Silvercorp's Kyzyltash Sulfide Gold Project in Kyrgyzstan, disclosing assay results from 29 diamond drill holes with significant gold intercepts (including 1.68 g/t Au over 212.5 metres in hole DH26M687). The disclosure describes exploration progress, resource expansion, and conversion of inferred resources into measured and indicated categories at an active mining project. This is an operational/exploration milestone rather than a discrete financial event, earnings announcement, or governance matter, making it an operational_other classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-19
EX-99.1
Aurora Cannabis announces the completion of an acquisition of Internode Pharma Limited and HAP Pharma Limited, UK-based licensed importer/wholesaler and pharmacy operations. The transaction involved a GBP 2.1 million cash payment and is described as "accretive" to adjusted EBITDA, providing direct ownership and control of the UK supply chain. This is a material acquisition expanding Aurora's international medical cannabis distribution footprint.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-19
EX-99.1
This press release announces the completion of a material transaction in which IsoEnergy contributed its Utah Portfolio (five permitted uranium mines and projects) to a newly formed entity, DISA Uranium Corporation, in exchange for 1,677,350 shares representing approximately 33% ownership. The transaction also involved a concurrent US$105 million private placement financing with IsoEnergy investing US$33 million. This constitutes a material disposition and change of control event that would significantly affect a reasonable investor's assessment of IsoEnergy's asset base and strategic positioning.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-08-19
The 6-K discloses that Braskem's Board of Directors has approved the hiring of Deloitte Touche Tohmatsu Auditores Independentes Ltda. to replace KPMG Auditores Independentes as the independent auditor for consolidated financial statements and quarterly information for fiscal years 2026 through 2028. This is a clear auditor change triggered by a change in shareholding structure and governance arrangement, with Deloitte beginning activities in Q3 2026.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-19
Banco Santander (Brasil) issued BRL 600.3 million in subordinated financial bills with a 10-year maturity and repurchase option starting in 2031. The proceeds are designated to compose Tier II Reference Equity under BCB Resolution No. 122, representing a material creation of a direct financial obligation that would affect a reasonable investor's assessment of the company's capital structure and leverage.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-08-19
TIM S.A. has approved a new share repurchase program (Program 9) authorizing acquisition of up to 55,187,638 common shares (approximately 2.31% of total shares) for up to R$1 billion, to be held in treasury or cancelled. The prior program (Program 8) acquired 46,884,500 shares with R$1 billion in disbursements, of which 28,678,509 were cancelled. Share repurchases constitute a return of capital to shareholders and fall within the dividend_distribution taxonomy as a capital allocation mechanism.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-08-19
The 6-K discloses minutes of an extraordinary Board of Directors meeting on August 19, 2026, approving a new Share Buyback Program (Program 9) authorizing acquisition of up to 55,187,638 common shares (2.31% of total shares) using approximately R$1 billion from profit reserves. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as they represent a distribution or return of capital to holders, distinct from a one-time special dividend but functionally similar in reducing equity and returning cash to shareholders.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-19
Item 7.01
JLL Income Property Trust announced the completion of a full cycle UPREIT transaction involving the acquisition of two properties (a light industrial property and medical outpatient building) from JLLX Diversified Portfolio III, DST. This is a material operational and strategic event involving a significant portfolio transaction ($1.3 million value increase over hold period, part of $1.5 billion in cumulative UPREIT transactions), but it does not fit the specific M&A taxonomy categories—it is neither a traditional acquisition/merger nor a disposition, but rather an internal restructuring of DST properties into REIT operating units via a 721 UPREIT mechanism. The transaction demonstrates the company's ability to execute on its JLL Exchange platform strategy and deliver tax-advantaged solutions to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
The Board elected Erik Olsson to serve as a director effective immediately on August 18, 2026. This is a clear appointment of a director to the Board, with Olsson's background as former Chairman, President and CEO of Mobile Mini and prior CEO of RSC Holdings indicating significant experience. The disclosure of his committee assignment (Audit Committee) and compensation arrangements confirms this is a material executive appointment under Item 5.02.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-19
Item 1.01
Kiora Pharmaceuticals entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation granting exclusive rights to develop, manufacture, and commercialize KIO-301 in South Korea. The transaction includes an upfront payment of $1.0 million, milestone payments, and double-digit royalties, expanding Kiora's global commercialization network for this clinical-stage molecular photoswitch.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
The primary disclosed action in Item 5.02(d) is the appointment of Susan B. Zaunbrecher to the boards of directors of LCNB Corp. and LCNB National Bank, effective August 18, 2026. While Item 5.02(e) also discloses new Change in Control Agreements with named executive officers, the filing centers on the director appointment as the lead event. Zaunbrecher's extensive background in banking, legal affairs, and corporate governance at Fifth Third Bancorp makes this a material board composition change for a community bank.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-19
Item 3.01
Trio-Tech International's common stock listing is being transferred from NYSE American (NYSE MKT) to Nasdaq Global Market, effective September 16, 2026, with trading on NYSE American ceasing on September 15, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-19
Item 2.02
Accuray disclosed financial results for the fourth quarter and fiscal year ended June 30, 2026, reporting total net revenue of $401.9 million (down 12% year-over-year), a GAAP net loss of $49.2 million ($0.40 per share), service revenue growth of 4%, and Adjusted EBITDA of $10.6 million, along with management commentary on transformation initiatives and financing activities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-19
Item 8.01
The CEO letter outlines Smartbird's strategic business direction and market positioning following its transformation from a footwear company (formerly Allbirds) into an AI infrastructure provider. The letter discusses the company's competitive strategy, target market (enterprises needing dedicated AI infrastructure), capital allocation discipline, and organizational principles. While this is a strategic communication rather than a discrete operational event, it represents a material articulation of the company's business model and growth strategy that would affect a reasonable investor's assessment of the registrant's direction and competitive positioning in the AI infrastructure market.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-19
Item 1.01
Loop Industries entered into two material definitive agreements on August 13, 2026: a License Agreement granting ELITe an exclusive, perpetual, royalty-bearing license to Loop's depolymerization technology for manufacturing and worldwide sales of rDMT, rMEG, and specialty polymers, and a Marketing Agreement appointing Loop as ELITe's exclusive sales and marketing representative with tiered fee structures.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-19
Item 8.01
Loop Industries disclosed entry into a Services Agreement with Ester on August 13, 2026, whereby Ester will provide operational services to ELITe including project management, post-incorporation assistance, and a license to use Ester's continuous polymerization process know-how, with a tiered royalty-like fee structure based on annual net sales of Licensed Products.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-19
Item 7.01
LGL Group announced its redomestication from Delaware to Nevada by statutory conversion, effective on or about September 1, 2026, following stockholder approval at the May 12, 2026 Annual Meeting. This is a governance event involving a change in jurisdiction of incorporation and governing law, but does not fit the specific categories of exec_departure, exec_appointment, exec_compensation, or shareholder_vote_results (the vote already occurred; this discloses the timing of implementation). The event is material as it affects the company's legal structure and governance framework, though operationally and economically the company states there will be no change to business, operations, management, assets, or liabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
The Board appointed Matthew Spanjers as a director effective August 13, 2026, and also appointed him to the compensation committee. While the disclosure includes standard director compensation details (cash and equity grants), the principal disclosed action is the appointment of a new director with significant food and beverage industry experience (former Chief Growth Officer of Krispy Kreme, McKinsey advisor). The appointment is material as it represents a change in board composition and governance, and notably Spanjers is a designee of Gateway Superfood investment entities under a December 2025 Investment Agreement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-19
Item 2.02
This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 19, 2026. Item 2.02 discloses quarterly financial results with a press release attached as Exhibit 99.1 showing Q2 2026 revenue of $8.6M (174% increase over Q1 2026, 21% YoY growth), gross margin of 17.8%, and net loss of $3.1M. The filing explicitly states "On August 19, 2026, Beam Global (the 'Company') issued a press release announcing financial results for its quarter ended June 30, 2026." This is material to investors as it provides the company's quarterly operating results and financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-19
Item 8.01
The filing discloses an at-the-market (ATM) offering agreement under which ASTC may sell up to $50 million of common stock through H.C. Wainwright & Co. as sales agent. The company has already sold 258,856 shares for $7.9 million under a prior prospectus supplement, and filed a new prospectus supplement on August 19, 2026 to increase the offering capacity to $50 million. This is a dilutive equity issuance that materially affects shareholder ownership and is a key capital-raising mechanism for small-cap companies.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-19
EX-99.1
Ferrovial announced selection to deliver Tennessee's I-24 Southeast Choice Lanes project, a $9.2 billion infrastructure development representing "the largest single capital investment and first public-private partnership in Tennessee's history." This is a material operational and strategic milestone—a major contract award in North America, Ferrovial's growth engine—but does not fit the discrete event categories (not M&A, not a financial obligation yet, not a periodic report). The operational_other classification captures a material business development that affects investor assessment of the company's growth trajectory and project pipeline.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-08-19
The 6-K discloses the appointment of two independent directors to the Board effective August 12, 2026: Mr. Jiwen Huang and Mr. Chuanjiang Xiao, both elected to fill vacancies and serve on the nominating committee. While the filing also mentions two director resignations (Wang and Liao), the principal disclosed action is the appointment of new directors to fill those vacancies, making this an exec_appointment event. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-19
EX-99.1
The press release announces commencement of production from an oil well investment project in Cold Lake, Alberta, representing a material expansion of CNEY's business strategy into North American oil production and supply chain services. While this is a significant operational and strategic milestone, it does not fit neatly into predefined event categories (not an M&A transaction, not a discrete financial obligation, not a workforce action). The disclosure is material because it signals a substantial strategic pivot and new revenue-generating asset for the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-19
The filing discloses entry into an Amended and Restated Stock Purchase Agreement dated July 22, 2026, under which First Choice Healthcare will acquire all issued and outstanding capital stock of three Florida corporations (Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., and Livewell MD, Inc.) and membership interests of Live Well Drugstore, LLC for a maximum purchase price of $21.306 million. This is a material acquisition of multiple operating entities with a substantial purchase price, conditioned upon and contemporaneous with a business combination with Westin Acquisition Corp.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-19
EX-99.1
This press release announces the expansion of Pulsenmore's home ultrasound technology into a major Israeli medical center (Lis Maternity and Women's Hospital at Ichilov), representing a material operational and commercial milestone. The disclosure describes a strategic partnership that broadens the company's market presence in Israel and demonstrates adoption of its core technology by a significant healthcare institution, which would affect a reasonable investor's assessment of the company's commercial traction and growth trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-19
EX-99.1
This exhibit announces successful completion of a first-in-human feasibility study for Colospan's novel intraoperative tissue assessment technology platform. The disclosure describes a clinical milestone—enrollment of 32 colorectal cancer patients, successful demonstration of technical feasibility, and establishment of a clinical foundation for continued development. This is a material operational/strategic milestone for a medical device company expanding its product pipeline beyond its lead product (CG-100), supporting Galmed's strategy to build a diversified portfolio in colorectal surgery. While not a discrete event type like M&A or exec change, it represents a significant clinical and operational achievement that would affect a reasonable investor's assessment of the company's pipeline and strategic execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
The filing discloses the appointment of two independent directors—Wei-Chieh Hao (appointed August 16, 2026) and Richard T. Betts (appointed August 18, 2026)—to the Board, with Hao also appointed as Chairperson of the Corporate Governance and Nominating Committee and Compensation Committee, and Betts as Chairperson of the Audit Committee. While the section also reports two director departures (Wong and Cheng), the principal disclosed actions center on the new appointments and their committee leadership roles, which are material governance changes for a SPAC. The departures are noted as non-contentious and are secondary to the appointment narrative.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-08-19
The filing discloses a corporate name change from "The Glimpse Group, Inc." to "Brightline Interactive, Inc." effective August 20, 2026, with a corresponding Nasdaq ticker symbol change from GGRP to BTLN (Item 5.03). While primarily a governance/administrative matter, the accompanying press release and CEO letter reveal a material strategic transformation: divestiture of non-core subsidiaries, new leadership and board (as of June 1, 2026), and a focused pivot to the Physical AI market around the SpatialCore platform. The name change reflects and signals this material business transformation, making it more than routine administrative disclosure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-19
The 6-K discloses completion of the acquisition of Landvision Inc. on August 7, 2026, with the Company issuing 30,000,000 ordinary shares representing approximately 87.72% of the enlarged issued shares. This is a material M&A completion involving substantial equity dilution and a change of control, meeting the definition of ma_activity under Item 1.01 or 2.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-19
The filing discloses Pre-Paid Purchase No. 5, a $100,000 investment by Streeterville Capital in an unsecured promissory note ($108,000 principal) that permits conversion into common stock at 90% of the lowest VWAP (floor $0.10/share), with a 9.99% beneficial ownership cap. Item 3.02 explicitly incorporates Item 1.01 and confirms unregistered sales under Section 4(a)(2) and Regulation D. This is a dilutive equity issuance mechanism, though the primary driver is also the company's financial distress (Floor Price trigger, mandatory repayments, workforce reduction of 20%).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-19
The filing discloses the completion of an acquisition of Zoolzy LLC by Earth Science Tech, Inc. on August 17, 2026, reported under Item 2.01 (Completion of Acquisition). The press release emphasizes strategic value through margin expansion, access to novel pharmaceutical ingredients, and entry into the veterinary market. Although the 8-K states the acquisition amount is "immaterial," the transaction is material to investors as it represents a strategic business combination with stated operational and financial benefits, and the company devoted a full press release to announce it.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-19
The 8-K discloses under Item 2.02 a press release announcing financial results for the three months and full fiscal year ended June 30, 2026. The press release reports record annual revenue of $4.2 million (38% YoY growth), gross profit of $2.05 million (64% YoY growth), and gross margin expansion to 48.63% (778 basis points improvement). Consolidated financial statements are included showing revenue, cost of revenue, operating expenses, and net loss. This is a standard earnings release disclosure material to investors assessing the company's financial performance and operational progress.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-19
This 8-K discloses the results of Glucotrack's August 18, 2026 annual meeting of stockholders under Item 5.07, reporting voting outcomes on five proposals: election of six directors, advisory say-on-pay vote, auditor ratification, reverse stock split approval, and warrant inducement approval. The filing presents detailed vote tallies (for, against, abstentions, broker non-votes) for each proposal, which is the core content and purpose of the disclosure.
View raw filing on EDGAR →